Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

  • CEO: Gordon Sanghera
  • Website:
  • Ticker symbol: Privately held
  • Headquarters: Oxford, UK
  • Number of employees: 250+

Oxford Nanopore said it is rolling out the LamPore test globally, initially in the UK, Germany, Switzerland, and the United Arab Emirates.

A clinical evaluation of LamPore, expected to be CE marked shortly, called it promising for high-throughput testing but recommended a more streamlined workflow.

The nanopore sequencing-based test is designed to both diagnose SARS-CoV-2 infection, as well as monitor mutations that may affect efforts to combat the virus.

The funding will be used to start a new trial to assess the benefits of repeat population testing, expand existing trials, and increase PCR-based testing capacity.

Both tests can detect SARS-CoV-2 in 90 minutes and will detect viruses like influenza and respiratory syncytial virus that tend to occur in the winter.

The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms

The method uses nanopore sequencing to analyze short cell-free DNA fragments from blood, providing results in as little as six hours.

Mere weeks after the 2019-nCoV sequence was released, firms, agencies, and research groups have already created PCR-based tests.

MinIon sequencing identified pathogens and antimicrobial resistance genes in the gut of preterm infants with suspected necrotizing enterocolitis.

A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.